293 related articles for article (PubMed ID: 15624201)
1. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
[TBL] [Abstract][Full Text] [Related]
2. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
3. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
4. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
[TBL] [Abstract][Full Text] [Related]
5. Shifts in expression of immunological cell markers in relapsed acute leukemia.
Tomová A; Babusíková O
Neoplasma; 2001; 48(3):164-8. PubMed ID: 11583283
[TBL] [Abstract][Full Text] [Related]
6. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
7. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
Zelezníková T; Babusíková O
Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
9. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
12. [Detection of minimal residual disease in patients with acute myeloid leukemia].
Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
[TBL] [Abstract][Full Text] [Related]
13. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
San-Miguel JF; Vidriales MB; Orfão A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):105-18. PubMed ID: 11987919
[TBL] [Abstract][Full Text] [Related]
14. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia.
van Wering ER; Beishuizen A; Roeffen ET; van der Linden-Schrever BE; Verhoeven MA; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1995 Sep; 9(9):1523-33. PubMed ID: 7658722
[TBL] [Abstract][Full Text] [Related]
16. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
Zheng J; Wang X; Hu Y; Yang J; Liu J; He Y; Gong Q; Yao J; Li X; Du W; Huang S
Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
[TBL] [Abstract][Full Text] [Related]
17. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
[TBL] [Abstract][Full Text] [Related]
18. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
19. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
[TBL] [Abstract][Full Text] [Related]
20. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.
Venditti A; Del Poeta G; Stasi R; De Fabriitis P; Coppetelli U; Bruno A; Simone MD; Papa G
Haematologica; 1993; 78(6):359-63. PubMed ID: 7513673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]